APGE (STOCKS)
Apogee Therapeutics, Inc. Common Stock
$134.400000
-0.150000 (-0.11%)
Prev close: $134.550000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Michael Henderson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $10,208.08M
- Employees
- 196
- P/E (TTM)
- -31.04
- P/B (TTM)
- 8.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
4
Buy
14
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-1.14 | $-1.09 | -0.0479 | -4.39% |
|
Mar 2026 (Q1)
|
$-1.06 | $-1.12 | +0.0635 | +5.65% |
|
Dec 2025 (Q4)
|
$-1.03 | $-1.08 | +0.0464 | +4.31% |
|
Sep 2025 (Q3)
|
$-1.11 | $-1.21 | +0.1027 | +8.47% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $328.11M |
| Research and Development | $240.74M |
| Other Operating Expenses | $87.37M |
| Operating Income/Loss | -$328.11M |
| Income/Loss From Continuing Operations After Tax | -$294.37M |
| Income/Loss From Continuing Operations Before Tax | -$294.09M |
| Income Tax Expense/Benefit | $280.00K |
| Net Income/Loss | -$294.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$294.37M |
| Net Income/Loss Available To Common Stockholders, Basic | -$294.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.34 |
| Diluted Earnings Per Share | -$4.34 |
| Basic Average Shares | 133,568,571 |
| Diluted Average Shares | 133,568,571 |
| Assets | $1.34B |
| Current Assets | $991.73M |
| Noncurrent Assets | $344.08M |
| Fixed Assets | $4.82M |
| Other Non-current Assets | $339.26M |
| Liabilities | $141.21M |
| Current Liabilities | $37.51M |
| Accounts Payable | $3.08M |
| Wages | $11.94M |
| Other Current Liabilities | $22.49M |
| Noncurrent Liabilities | $103.70M |
| Equity | $1.19B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.19B |
| Liabilities And Equity | $1.34B |
| Net Cash Flow From Operating Activities | -$243.89M |
| Net Cash Flow From Operating Activities, Continuing | -$243.89M |
| Net Cash Flow From Investing Activities | -$687.89M |
| Net Cash Flow From Investing Activities, Continuing | -$687.89M |
| Net Cash Flow From Financing Activities | $912.87M |
| Net Cash Flow From Financing Activities, Continuing | $912.87M |
| Net Cash Flow | -$18.92M |
| Net Cash Flow, Continuing | -$18.92M |
| Comprehensive Income/Loss | -$297.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$297.56M |
| Other Comprehensive Income/Loss | -$68.21M |